📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
GKSL Reports Zero Deviation in Utilization of ₹250.80 Crore IPO Proceeds
Gujarat Kidney And Super Speciality Limited (GKSL) has submitted its statement of deviation for the quarter ended December 31, 2025, confirming that the ₹250.80 crore raised via equity issuance is being handled as per the original objects. The funds were raised on December 24, 2025, and as of the quarter-end, no deviations or variations in utilization were reported. Major allocations include ₹77 crore for the acquisition of Parekhs Hospital and ₹30.10 crore for a new women's hospital in Vadodara. Brickwork Ratings India Private Limited is acting as the monitoring agency for these funds.
Key Highlights
Raised a total of ₹250.80 crore through an equity share issue on December 24, 2025.
Reported zero deviation or variation in the use of proceeds for the third quarter of FY26.
Allocated ₹77 crore for the acquisition of Parekhs Hospital Private Limited at Ahmedabad.
Earmarked ₹30.10 crore for capital expenditure for a new women's healthcare hospital in Vadodara.
Allocated ₹87.44 crore for inorganic growth through unidentified acquisitions and general corporate purposes.
💼 Action for Investors
Investors should track subsequent quarterly reports to ensure the timely and efficient deployment of funds into the stated acquisition and expansion projects. The successful execution of these capital-intensive projects will be a key driver for the company's long-term growth.
GKSL Q3 FY26 Standalone PAT Grows 5.4% YoY to ₹2.33 Cr; Revenue Up 14.8%
Gujarat Kidney And Super Speciality Limited (GKSL) reported a steady performance for the quarter ended December 31, 2025, with standalone revenue from operations rising 14.8% YoY to ₹976.45 Lacs. Net profit for the quarter saw a modest increase to ₹233.26 Lacs from ₹221.20 Lacs in the previous year. For the nine-month period, the company achieved a PAT of ₹853.36 Lacs, representing an 8.8% growth compared to the same period last year. However, bottom-line growth was slightly constrained by a significant jump in finance costs and other operating expenses.
Key Highlights
Standalone Revenue from Operations increased to ₹976.45 Lacs in Q3 FY26 from ₹850.64 Lacs in Q3 FY25.
Standalone Profit After Tax (PAT) for the quarter stood at ₹233.26 Lacs, up 5.4% year-on-year.
Nine-month (9M FY26) Standalone PAT reached ₹853.36 Lacs compared to ₹784.42 Lacs in 9M FY25.
Finance costs for the quarter rose sharply to ₹29.22 Lacs from ₹10.68 Lacs in the corresponding quarter last year.
The Board approved consolidated results including subsidiaries Raj Palmland Hospital and Harmony Medicare.
💼 Action for Investors
Investors should note the steady revenue growth in the healthcare segment but remain cautious about rising finance costs which may impact margins. The stock's performance will likely depend on the successful integration and contribution of its newly consolidated hospital subsidiaries.
GKSL to Acquire 51% Stake in Patel Pharmacy and Patel Multispeciality Hospital for ₹12.50 Crore
Gujarat Kidney And Super Speciality Limited (GKSL) has approved the acquisition of a 51% controlling stake in two entities: Patel Pharmacy and Patel Multispeciality Hospital and ICU. The total cash consideration for these acquisitions is approximately ₹12.50 crore, with ₹3.70 crore allocated for the pharmacy and ₹8.80 crore for the hospital. Both target entities are based in Ankleshwar, Gujarat, and have been operational since 2015. This strategic move is aimed at consolidating GKSL's position in the healthcare sector and diversifying its service portfolio beyond specialized kidney care.
Key Highlights
Acquisition of 51% stake in Patel Pharmacy for ₹3.70 crore (FY25 turnover: ₹2.57 crore)
Acquisition of 51% stake in Patel Multispeciality Hospital and ICU for ₹8.80 crore (FY25 turnover: ₹6.46 crore)
Total investment of ₹12.50 crore to be completed via cash consideration within approximately 2 months
Strategic expansion into multispeciality healthcare and pharmacy services to diversify business portfolio
Target entities are established firms in Ankleshwar, Gujarat, with a track record dating back to 2015
💼 Action for Investors
Investors should view this as a growth-oriented move that diversifies the company's revenue streams. Monitor the integration of these assets and their contribution to consolidated margins in the next few quarters.
GKSL to Acquire 49% Stake in Harmony Medicare for ₹10.78 Cr and Ashwini Medical for ₹14 Cr
Gujarat Kidney And Super Speciality Limited (GKSL) is consolidating its healthcare portfolio by acquiring the remaining 49% of Harmony Medicare for ₹10.78 Crores, bringing its ownership to 100%. The company is also completing the acquisition of Ashwini Medical Centre for a total of ₹14 Crores, utilizing ₹12.40 Crores from its IPO proceeds for the final payment. Harmony Medicare has shown strong revenue growth, reaching ₹42.29 Crores in FY25 compared to ₹27.70 Crores in FY23. These moves are expected to be finalized within two months and aim to strengthen GKSL's market position in Gujarat.
Key Highlights
Acquisition of 49% stake in Harmony Medicare for ₹10.78 Crores to achieve 100% ownership
Harmony Medicare's revenue increased by 52.6% over two years, reaching ₹42.29 Crores in FY25
Approval of ₹12.40 Crores payment from IPO funds for the ₹14 Crores acquisition of Ashwini Medical Centre
Ashwini Medical Centre, a partnership firm, reported a turnover of ₹4.51 Crores for FY25
Both acquisitions are targeted for completion within a two-month timeframe
💼 Action for Investors
Investors should view these acquisitions as a positive step toward scale and consolidation of high-growth subsidiaries. Monitor the integration of these entities and their impact on consolidated margins in the upcoming quarterly results.
GKSL to Acquire 100% Stake in Parekhs Hospital for Rs 77 Crore
Gujarat Kidney And Super Speciality Limited (GKSL) has announced the 100% acquisition of Parekhs Hospital Private Limited for a cash consideration of Rs 77 crore. Parekhs Hospital is an Ahmedabad-based healthcare provider with a steady turnover, reporting Rs 25.67 crore in FY 2024-25. The acquisition is intended to strengthen GKSL's presence in the healthcare sector and diversify its business portfolio. The transaction is expected to be completed within approximately two months, making Parekhs Hospital a wholly-owned subsidiary.
Key Highlights
Acquisition of 100% equity stake (2,55,000 shares) in Parekhs Hospital Private Limited for Rs 77 crore.
Target company reported consistent annual turnover: Rs 25.67 Cr (FY25), Rs 26.36 Cr (FY24), and Rs 24.08 Cr (FY23).
The deal is a pure cash consideration and is expected to close within 2 months.
Parekhs Hospital has been operational since 2006 and is located in Ahmedabad, Gujarat.
💼 Action for Investors
Investors should view this as a significant inorganic growth move, though they should monitor how GKSL funds the Rs 77 crore acquisition and its impact on future debt-to-equity levels.